The purpose of this study is to understand how COVID-19 affects people's ability to workand to calculate the costs associated with loss of work.The study compares two groups of participants who are confirmed to have mild-to moderatedCOVID-19 and who have high chances of the disease becoming severe.The two groups are:People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid)People who were eligible to receive antiviral medication but did not receive any.The participants will be selected from various health databases in the US between June2021 and December 2022.The main goals are:To look at the characteristics of both groups of participants with COVID-19. To measurehow much work these participants missed, including days off and sick leave, and the costsassociated with this work loss.To compare work loss and costs between the two groups of participants, consideringdifferences in their clinical and demographic characteristics.The study will evaluate at least 30 days of data from participants after they areconfirmed to have COVID-19
Not Provided
Drug: nirmatrelvir-ritonavir
Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at
high-risk for progressing to severe disease
Other Name: Paxlovid
Inclusion Criteria:
- >1 non-diagnostic2 outpatient medical claim in the MarketScan Commercial or Medicare
Database with the International Classification of Diseases, 10th Revision (ICD-10)
diagnosis code for COVID-19 (U071) between December 16, 2021 (5 days prior to the
date of emergency use authorization of NMV/r) and December 1, 2022 (30 days prior to
the end of available HPM data); the date of the earliest qualifying claim is the
index date.
- Primary beneficiary on their insurance policy (i.e., eligible for inclusion in the
MarketScan HPM Database)
- >6 months of continuous enrollment with medical and pharmacy benefits in the
MarketScan Commercial or Medicare Database before the index date (baseline period)
- >30 days of continuous enrollment with medical and pharmacy benefits in the
MarketScan Commercial or Medicare Database after and including the index date
(minimum follow-up period)
- Treated cohort ONLY: ≥1 claim for Paxlovid within 5 days of index (index date and
next 4 days)
Exclusion Criteria:
- Evidence of death on the index date or the following day
- Any inpatient admission on the index date or the following day
- ≥1 inpatient claim with a COVID-19 diagnosis in any position on the claim during the
30 days before the index date
- >1 non-diagnostic claim with a diagnosis code for stage 4 or stage 5 chronic kidney
disease, end stage renal disease, or a procedure code for dialysis, during the
baseline period or on the index date
Pfizer New York
New York, New York, United States
Pfizer CT.gov Call Center, Study Director
Pfizer